Spatially fractionated radiotherapy versus conventional radiotherapy in the treatment of soft tissue sarcoma: A multicenter, prospective, phase II, randomized controlled clinical trial protocol
Precision Radiation Oncology · 2026-03 · 10 (1) · 59-64
DOI: 10.1002/pro6.70046 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Precision Radiation Oncology, online erschienen am 22.01.2026. Verfasst von Peng Shang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Innovative Institute of Chinese Medicine and Pharmacy Shandong University of Traditional Chinese Medicine Jinan China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
Soft tissue sarcoma (STS) is a rare and highly heterogeneous malignancy. Conventional radiotherapy (CRT) often shows limited efficacy, especially in radioresistant subtypes, such as liposarcoma and fibrosarcoma, with local recurrence rates ranging from 10% to 30%. Spatially fractionated radiotherapy (SFRT), a technique that delivers non‐uniform high‐dose distributions, has shown promise in improving tumor control and potentially stimulating immune responses in preliminary studies.
Methods
This multicenter, prospective, randomized phase II trial aims to enroll 106 patients aged 18–70 years with pathologically confirmed STS and a minimum tumor diameter ≥5 cm. Participants will be randomized 1:1 into SFRT or CRT groups. CRT involves a uniform dose of 3.0 Gy per fraction over 15–20 fractions. SFRT employs a non‐uniform dose distribution, supplementing CRT with high‐dose spot irradiation of 8–15 Gy per fraction delivered for a total of 3–4 fractions. The primary endpoint was the objective response rate, and the secondary endpoints included local control, progression‐free survival, and safety.
Discussion
This trial is the first randomized study to directly compare SFRT and CRT for STS. SFRT is expected to enhance tumor control and elicit immunomodulatory effects, particularly in radioresistant tumors. However, the potential acute toxicities and technical complexities warrant further evaluation. Future studies should investigate the synergistic potential of SFRT combined with immunotherapy.
Trial registration
The study was registered at ClinicalTrials.gov with the Identifier: NCT06980259 (Registered 12th May 2025).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Innovative Institute of Chinese Medicine and Pharmacy Shandong University of Traditional Chinese Medicine Jinan China.
- Department of Radiation Oncology Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences 440 Jiyan Road Jinan Shandong China.
- Department of Radiotherapy Sun Yat-sen Memorial Hospital Sun Yat-sen University Guangzhou China.
ORCID-Profile: Peng Shang, Jinbo Yue
Zitieren
APA
Shang, P., Li, M., Zhang, X., Zhu, D., & Yue, J. (2026). Spatially fractionated radiotherapy versus conventional radiotherapy in the treatment of soft tissue sarcoma: A multicenter, prospective, phase II, randomized controlled clinical trial protocol. Precision Radiation Oncology, 10(1), 59-64. https://doi.org/10.1002/pro6.70046
Vancouver
Shang P, Li M, Zhang X, Zhu D, Yue J. Spatially fractionated radiotherapy versus conventional radiotherapy in the treatment of soft tissue sarcoma: A multicenter, prospective, phase II, randomized controlled clinical trial protocol. Precision Radiation Oncology. 2026;10(1):59-64. doi:10.1002/pro6.70046
BibTeX
@article{Shang2026,
author = {Shang, Peng and Li, Minghao and Zhang, Xiang and Zhu, Dongyuan and Yue, Jinbo},
title = {Spatially fractionated radiotherapy versus conventional radiotherapy in the treatment of soft tissue sarcoma: A multicenter, prospective, phase II, randomized controlled clinical trial protocol},
journal = {Precision Radiation Oncology},
year = {2026},
volume = {10},
number = {1},
pages = {59--64},
doi = {10.1002/pro6.70046}
}
EUVIMED